Rajarajan S, Korlimarla A, Alexander A, Anupama CE, Ramesh R, Srinath BS, Sridhar TS, Prabhu JS. Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes. Frontiers in endocrinology. 2021:716.( IF-3.675)
Desai K, Aiyappa R, Prabhu JS, Nair MG, Lawrence PV, Korlimarla A, Ce A, Alexander A, Kaluve RS, Manjunath S, Correa M. HR+ HER2- breast cancers with growth factor receptor–mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells. Tumor Biology. 2017 Mar;39(3):1010428317695028. (IF-3.6)
Prabhu JS, Korlimarla A, Anupama CE, Alexander A, Raghavan R, Kaul R, Desai K, Rajarajan S, Manjunath S, Correa M, Raman R. Dissecting the biological heterogeneity within hormone receptor positive her2 negative breast cancer by gene expression markers identifies indolent tumors within late stage disease. Translational oncology. 2017 Aug 1;10(4):699-706.(IF4.2)
Korlimarla A, Prabhu JS, Remacle J, Rajarajan S, Raja U, CE A, Srinath BS, Manjunath S, KS G, Correa M, MSN P. Identification of BRCA1 deficiency using multi-analyte estimation of BRCA1 and its repressors in FFPE tumor samples from patients with triple negative breast cancer. PloS one. 2016 Apr 14;11(4):e0153113.(IF3.2)
Desai K, Nair MG, Prabhu JS, Vinod A, Korlimarla A, Rajarajan S, Aiyappa R, Kaluve RS, Alexander A, Hari PS, Mukherjee G. High expression of integrin ?6 in association with the Rho–Rac pathway identifies a poor prognostic subgroup within HER 2 amplified breast cancers. Cancer medicine. 2016 Aug;5(8):2000-11.(IF-3.36)
Korlimarla A, Prabhu JS, Anupama CE, Remacle J, Wahi K, Sridhar TS. Separate quality-control measures are necessary for estimation of RNA and methylated DNA from formalin-fixed, paraffin-embedded specimens by quantitative PCR. The Journal of molecular diagnostics. 2014 Mar 1;16(2):253-60.(IF5.5)
Prabhu JS, Korlimarla A, Desai K, Alexander A, Raghavan R, Anupama CE, Dendukuri N, Manjunath S, Correa M, Raman N, Kalamdani A. A majority of low (1-10%) ER positive breast cancers behave like hormone receptor negative tumors. Journal of Cancer. 2014;5(2):156.(IF-3.1)
Exploring new techniques in histopathology; Maintenance of biorepository.